Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
Together, they discuss Rosana and Marty's recent publication regarding a virus-like element in our genome known as LINE-1. LINE-1, part of our "dark genome," was ignored as junk DNA for years, but is increasingly recognized to contribute to the pathology of autoimmunity, cancer, neurodegeneration, and aging. Rosana and Marty discuss how the discovery was made as well as how Rome Therapeutics is developing a platform to target LINE-1 and other factors that are part of the "dark genome" for the treatment of disease.
Additional reading:
AI in Pharmaceutical R&D with Kim Branson
Unleashing CAR T with Carl June
Longevity as a Health Asset with Tom Hale
The Power of Drug Discovery with Philip Tagari
AI-Enabled Continuity of Care with Ed and Todd Park
Grand Challenges in Healthcare AI with Vijay Pande and Julie Yoo
Adapting Biopharma to AI with Greg Meyers
Behind the Buy: Payors and Providers on AI Adoption
Biotech Revolution with Software Engineering Daily
DNA as Data Storage with Vijay Pande
The Most Interesting Healthcare Companies You've Never Heard Of with Julie Klapstein
CRISPR by Design with Benjamin Oakes
Metrics for a Complex Machine with Josh Clemente
Transitioning From Gymnast to Investor with Aly Raisman
Finding PMF in Healthcare (After Tasting it Elsewhere) with Eren Bali and Max Cohen
IRA, AI Regulation, and the Future with Joe Grogan
Drag & Drop Genome Editing
Past, Present, and Future of AI with Vijay Pande
Fireside Chat with Sean Duffy
Create your
podcast in
minutes
It is Free